Skip to main content
Premium Trial:

Request an Annual Quote

Organon Will Use Gene Logic's Gene Express in Drug Discovery Effort

Premium

COLUMBIA, Md.--Gene Logic here has signed an agreement granting three years of access to its Gene Express Normal database of gene expression profiles to NV Organon, a pharmaceutical business unit of Akzo Nobel. As part of the collaboration, Gene Logic will also build a gene expression database for drug target discovery specific to certain of Organon's research programs. Gene Express includes a variety of human, rat, and mouse tissues, and a proprietary bioinformatics system to analyze and integrate the information.

The agreement gives Gene Logic annual research funding, database license fees, milestone payments, and royalties on product sales, plus rights to diagnostics and certain categories of therapeutics. Organon can develop and commercialize any drugs that result from the partnership. Research will be directed toward drugs for use against gynecological, psychiatric, and cardiovascular diseases, among others, according to Driek Vergouwen, Organon's managing director of research and development. "The alliance allows Organon to strengthen its drug discovery pipeline and leverage its investments in combinatorial chemistry and high-throughput screening," remarked Michael Brennan, Gene Logic's president and CEO.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.